Core Viewpoint - The article highlights the significant growth and international recognition of China's innovative pharmaceuticals, with a total authorization amount exceeding $60 billion in the first quarter of 2026, indicating a strong development trend during the 14th Five-Year Plan period [3]. Group 1: Innovative Drug Authorization - In the first quarter of 2026, China's innovative drug authorization total exceeded $60 billion, approaching half of the total for the entire year of 2025, which was a record $130 billion [3]. - In 2025, China approved a record 76 innovative drugs, marking a historical high for the country [3]. - As of March 27, 2026, the National Medical Products Administration (NMPA) approved 10 new drugs, with 8 being original innovations from China [3]. Group 2: Regulatory Framework Enhancements - The NMPA plans to enhance the policy framework to encourage, protect, and serve innovation, focusing on four key areas [4]. - A comprehensive revision of the Drug Administration Law will take effect on May 15, 2026, with over 90% of its provisions being updated to reflect recent regulatory reforms [4]. - The revised law aims to accelerate drug registration processes for pediatric and rare disease treatments, providing market exclusivity and data protection for innovative drugs [4]. Group 3: Safety and Quality Assurance - In 2025, the NMPA handled over 105,800 cases to eliminate safety risks, maintaining a drug inspection pass rate of over 99% [5]. - The NMPA will enhance regulatory collaboration across regions and levels, utilizing digital and intelligent methods to improve the efficiency of drug regulation [5]. Group 4: Scientific and Technical Support - The NMPA emphasizes the implementation of a regulatory science action plan, focusing on cutting-edge fields such as cell and gene therapy, AI drug development, and brain-machine interfaces [6]. - The agency aims to align China's drug registration technical requirements with international standards and participate in global regulatory coordination [7]. Group 5: Capacity Building and Local Initiatives - The NMPA is committed to building professional technical teams to enhance the precision and scientific level of drug regulation in key areas [8]. - Regional centers have been established to support drug and medical device review processes, with Beijing leading in the approval of innovative drugs and high-end medical devices [9].

Group 1 - The National Medical Products Administration has announced the list of regulatory science innovation research bases, with Chengdu Institute of Drug Inspection and Research being selected as the only drug inspection institution in Western China to establish a research base in the field of traditional Chinese medicine [1] - The research base will focus on fundamental, key, and cutting-edge technological issues related to drug research and development, production, and quality control, aiming to enhance the scientific, standardized, and international level of drug regulation [1] - Chengdu's traditional Chinese medicine industry has a strong foundation, with an estimated comprehensive output value of approximately 28 billion yuan in 2024, and 126 large-scale enterprises in the sector [1] Group 2 - The area of traditional Chinese medicinal material cultivation exceeds 600,000 acres, with 9 national geographical indication products and an annual export value of 150 million yuan for medicinal materials and extracts [1] - The Hehua Pond traditional Chinese medicinal material market is projected to rank among the top three in the country in terms of scale and efficiency in 2024, and has released the first national traditional Chinese medicinal material commodity index [1] - The development pattern of the industry is characterized by a full-chain approach encompassing cultivation, research, production, and trade [1]